PAI Partners to Acquire Elemis from L’Occitane
The French private equity group announced on Wednesday that it will buy the UK skin and body care brand for an undisclosed sum.

This week, everyone will be talking about how Kering will address its various Gucci-related controversies, London Fashion Week kicking off with yet another Brexit vote and Frieze Los Angeles joining a crowded fashion calendar. Read our BoF Professional Cheat Sheet.

The world's biggest beauty company reported forecast-beating sales figures for the fourth quarter, but disappointment about margins dampened enthusiasm.

The owner of Kate Spade and Coach missed both its own and analysts’ expectations in the latest quarter and cut its guidance.

The British fashion group's shares have slumped 70 percent over the last year and reported a 1.5 percent fall in revenue in the Christmas quarter.

Higher demand for luxury skincare products with brands such as La Mer, Mac Cosmetics and Origins, and growth in the Asia-Pacific region sent shares up 10 percent.

This week, everyone will be talking about LVMH's annual results, the end of the government shutdown and Amazon's improving fashion sense. Read our BoF Professional Cheat Sheet.

Same-store sales fell 2 percent during the holiday shopping season as Chinese tourists bought less jewellery, Tiffany's net sales also fell, about 1 percent to $1.04 billion.

The Spanish group missed third-quarter profit estimates and shares slipped 4.5 percent in initial trading, but like-for-like sales at the end of November grew 3 percent after a good start to the season.
The French private equity group announced on Wednesday that it will buy the UK skin and body care brand for an undisclosed sum.
At its capital markets event in Shanghai, leadership said it aims to deliver mid-single-digit organic net sales growth through fiscal 2030, and unveiled a new cost-cutting and strategic roadmap.
The Indian beauty retailer said on Wednesday its second-quarter profit nearly tripled, as improved operating efficiency and strong demand for premium beauty products boosted margins.
The US retailer is planning to spin off its pharmacy business in what would be one of the biggest-ever breakups in the healthcare industry, according to reports.
The jeweller edged up its near-term revenue and profitability targets as efforts to keep the brand affordable pay off.
The Ozempic maker raised its full-year outlook for the third time this year on Wednesday as its Wegovy pill beat third-quarter sales forecasts, boosting the Danish firm's bid to win back ground from US rival Eli Lilly.
The fragrance firm reported third-quarter core profit a touch above market expectations on Wednesday, and raised its full-year growth outlook but failed to impress investors.
Sales and profit from clothing and homeware remain below two years ago but ‘brand is in good health.’